Compare Navitas Semiconductor Corporation Common Stock (NVTS) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Navitas Semiconductor Corporation Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Navitas Semiconductor Corporation Common Stock trades at $10.7 (market cap $2.87B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.74 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 8.8× Navitas Semiconductor Corporation Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Navitas Semiconductor Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Navitas Semiconductor Corporation Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| NVTS | RPRX | |
|---|---|---|
Market Cap | $2.87B | $25.27B |
Volume | 13,752,519 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $31.79 | $63.96 |
52-Week Low | $7.14 | $35.44 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.32B | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Navitas Semiconductor Corporation Common Stock
Navitas Semiconductor designs and markets gallium nitride and silicon carbide power semiconductors. Its products are used in power conversion and charging for data centers, energy infrastructure, and industrial applications.
Read more on NVTS →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
